{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T04:16:12Z","timestamp":1793247372694,"version":"4.5.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T00:00:00Z","timestamp":1757894400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T00:00:00Z","timestamp":1757894400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Ther"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s40121-025-01229-9","type":"journal-article","created":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T09:46:35Z","timestamp":1757929595000},"page":"2551-2563","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["The Role of Protease Inhibitors in HIV Treatment: Who Still Needs Them in 2025?"],"prefix":"10.1007","volume":"14","author":[{"given":"Abiu","family":"Sempere","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo","family":"Alonso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leire","family":"Berrocal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Calvo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Foncillas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iv\u00e1n","family":"Chivite","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorena","family":"de la Mora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexy","family":"Inciarte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berta","family":"Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Mart\u00ednez-Rebollar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Montserrat","family":"Laguno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Gonz\u00e1lez-Cord\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Luis","family":"Blanco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esteban","family":"Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 M.","family":"Mir\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"de Lazzari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josep","family":"Mallolas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0048-5506","authenticated-orcid":false,"given":"Juan","family":"Ambrosioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,15]]},"reference":[{"issue":"10","key":"1229_CR1","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1007\/s40265-018-0934-2","volume":"78","author":"ED Deeks","year":"2018","unstructured":"Deeks ED. Darunavir\/cobicistat\/emtricitabine\/tenofovir alafenamide: a review in HIV-1 infection. Drugs. 2018;78(10):1013\u201324.","journal-title":"Drugs"},{"key":"1229_CR2","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s40265-019-01247-1","volume":"80","author":"LJ Scott","year":"2020","unstructured":"Scott LJ. Dolutegravir\/lamivudine single-tablet regimen: a review in HIV-1 infection. Drugs Adis. 2020;80:61\u201372.","journal-title":"Drugs Adis"},{"key":"1229_CR3","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1007\/s40265-018-1010-7","volume":"78","author":"ED Deeks","year":"2018","unstructured":"Deeks ED. Bictegravir\/emtricitabine\/tenofovir alafenamide: a review in HIV-1 infection. Drugs. 2018;78:1817\u201328.","journal-title":"Drugs"},{"issue":"3","key":"1229_CR4","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1097\/QAD.0000000000003772","volume":"38","author":"I Jarr\u00edn","year":"2024","unstructured":"Jarr\u00edn I, Rava M, Del Romero Raposo J, et\u00a0al. Life expectancy of people with HIV on antiretroviral therapy in Spain. AIDS. 2024;38(3):387\u201395. https:\/\/doi.org\/10.1097\/QAD.0000000000003772.","journal-title":"AIDS"},{"key":"1229_CR5","unstructured":"European AIDS Clinical Society (EACS). EACS Guidelines Version 12.0. October 2023. https:\/\/www.eacsociety.org\/guidelines"},{"key":"1229_CR6","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Department of Health and Human Services. 2024. https:\/\/clinicalinfo.hiv.gov"},{"issue":"3","key":"1229_CR7","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0228822","volume":"15","author":"B Neesgaard","year":"2020","unstructured":"Neesgaard B, Hentzien M, Neesgaard A, et\u00a0al. Outcomes of people living with HIV according to third drug class: a prospective observational study in the RESPOND cohort consortium. PLoS ONE. 2020;15(3):e0228822. https:\/\/doi.org\/10.1371\/journal.pone.0228822.","journal-title":"PLoS ONE"},{"issue":"4","key":"1229_CR8","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.25484","volume":"23","author":"K Bourgi","year":"2020","unstructured":"Bourgi K, Rebeiro PF, Turner M, et\u00a0al. Weight gain among treatment-na\u00efve persons with HIV starting integrase inhibitors compared to non-nucleoside reverse transcriptase inhibitors or protease inhibitors in a large observational cohort in the United States and Canada. J Int AIDS Soc. 2020;23(4):e25484. https:\/\/doi.org\/10.1002\/jia2.25484.","journal-title":"J Int AIDS Soc"},{"issue":"2","key":"1229_CR9","doi-asserted-by":"publisher","first-page":"ofab005","DOI":"10.1093\/ofid\/ofab005","volume":"8","author":"MA Spinelli","year":"2021","unstructured":"Spinelli MA, Hickey MD, Glidden DV, et\u00a0al. Virologic outcomes of rapid antiretroviral therapy initiation in those with low CD4 cell counts. Open Forum Infect Dis. 2021;8(2):ofab005. https:\/\/doi.org\/10.1093\/ofid\/ofab005.","journal-title":"Open Forum Infect Dis"},{"issue":"4","key":"1229_CR10","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-059883","volume":"12","author":"A d\u2019Arminio Monforte","year":"2022","unstructured":"d\u2019Arminio Monforte A, Cozzi-Lepri A, Antinori A, et\u00a0al. HIV drug resistance mutations in patients failing boosted PIs and in PI-na\u00efve patients: a real-life study. BMJ Open. 2022;12(4):e059883. https:\/\/doi.org\/10.1136\/bmjopen-2021-059883.","journal-title":"BMJ Open"},{"issue":"8","key":"1229_CR11","doi-asserted-by":"publisher","first-page":"2230","DOI":"10.1093\/jac\/dkx142","volume":"72","author":"RS Boerma","year":"2017","unstructured":"Boerma RS, Sigaloff KC, Akanmu AS, et\u00a0al. High levels of HIV drug resistance in adult patients failing first-line antiretroviral therapy in Nigeria. J Antimicrob Chemother. 2017;72(8):2230\u20138. https:\/\/doi.org\/10.1093\/jac\/dkx142.","journal-title":"J Antimicrob Chemother"},{"issue":"22","key":"1229_CR12","doi-asserted-by":"publisher","first-page":"2730","DOI":"10.1097\/CM9.0000000000002510","volume":"135","author":"Q Peng","year":"2022","unstructured":"Peng Q, Liu X, Tang X, Zhang Q, Zhao J, Zheng C, et\u00a0al. Low rate of pre-exposure prophylaxis and post-exposure prophylaxis uptake and high prevalence of transmitted drug resistance among newly diagnosed primary HIV infections in Shenzhen, China: a real-world retrospective study. Chin Med J (Engl). 2022;135(22):2730\u20137.","journal-title":"Chin Med J (Engl)"},{"issue":"3","key":"1229_CR13","doi-asserted-by":"publisher","first-page":"e166","DOI":"10.1016\/S2352-3018(20)30271-X","volume":"8","author":"J Ambrosioni","year":"2021","unstructured":"Ambrosioni J, Petit E, Liegeon G, Laguno M, Mir\u00f3 JM. Primary HIV-1 infection in users of pre-exposure prophylaxis. Lancet HIV. 2021;8(3):e166\u201374. https:\/\/doi.org\/10.1016\/S2352-3018(20)30271-X.","journal-title":"Lancet HIV"},{"issue":"7","key":"1229_CR14","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1056\/NEJMoa2101016","volume":"385","author":"RJ Landovitz","year":"2021","unstructured":"Landovitz RJ, Donnell D, Clement ME, Hanscom B, Cottle L, Coelho L, et\u00a0al. Cabotegravir for HIV prevention in cisgender men and transgender women. N Engl J Med. 2021;385(7):595\u2013608.","journal-title":"N Engl J Med"},{"key":"1229_CR15","unstructured":"Long-acting injectable cabotegravir + rilpivirine for HIV maintenance therapy: week 48 pooled analysis of phase 3 ATLAS and FLAIR Trials. J Acquir Immune Defic Syndr [Internet]. 85(4). Available from: www.jaids.com"},{"issue":"10267","key":"1229_CR16","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1016\/S0140-6736(20)32666-0","volume":"396","author":"ET Overton","year":"2020","unstructured":"Overton ET, Richmond G, Rizzardini G, Jaeger H, Orrell C, Nagimova F, et\u00a0al. Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS- 2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study. The Lancet. 2020;396(10267):1994\u20132005.","journal-title":"The Lancet"},{"key":"1229_CR17","volume-title":"Update on HIV treatment and monitoring\u2014Use of dolutegravir and viral load testing","author":"World Health Organization","year":"2019","unstructured":"World Health Organization. Update on HIV treatment and monitoring\u2014Use of dolutegravir and viral load testing. Geneva: WHO; 2019."},{"issue":"4","key":"1229_CR18","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1056\/NEJMoa2101609","volume":"385","author":"N Paton","year":"2021","unstructured":"Paton N, Musaazi Kityo C, Walimbwa S, Hoppe A, Balyegisawa A, et\u00a0al. Dolutegravir or darunavir in combination with zidovudine or tenofovir to treat HIV. N Engl J Med. 2021;385(4):330\u201341.","journal-title":"N Engl J Med"},{"key":"1229_CR19","unstructured":"HIV monitoring foundation (Stichting HIV Monitoring). Monitoring Report 2020. Amsterdam: SHM; 2020. https:\/\/www.hiv-monitoring.nl"}],"container-title":["Infectious Diseases and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-025-01229-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40121-025-01229-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-025-01229-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T06:03:20Z","timestamp":1760076200000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40121-025-01229-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,15]]},"references-count":19,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["1229"],"URL":"https:\/\/doi.org\/10.1007\/s40121-025-01229-9","relation":{},"ISSN":["2193-8229","2193-6382"],"issn-type":[{"value":"2193-8229","type":"print"},{"value":"2193-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,15]]},"assertion":[{"value":"21 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Abiu Sempere has received personal compensation from presentations from Gilead, ViiV and J&J outside of the submitted work. Juan Ambrosioni has received research funding from ViiV and Gilead; has participated in Advisory Boards for ViiV, Gilead, MSD, and J&J; has received personal compensation for presentations from ViiV, Gilead, MSD, and J&J; and has participated in \u00a0Data Safety Monitoring Boards for HIPRA and Grifols, outside of the submitted work. Juan Ambrosioni is an Editorial Board member of Infectious Diseases and Therapy. Juan Ambrosioni was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Jos\u00e9 M. Mir\u00f3 has received consulting honoraria and\/or research grants from Angelini, Basilea, Contrafect, Cubist, Genentech, Gilead Sciences, Jansen, Medtronic, MSD, Novartis, Pfizer, and ViiV Healthcare outside the submitted work. Rodrigo Alonso, Leire Berrocal, Julia Calvo, Alberto Foncillas, Iv\u00e1n Chivite, Lorena de la Mora,\u00a0Alexy Inciarte, Berta Torres, Mar\u00eda Mart\u00ednez-Rebollar,\u00a0Montserrat Laguno, Ana Gonz\u00e1lez-Cord\u00f3n, Jos\u00e9 Luis Blanco, Esteban Mart\u00ednez, Elisa de Lazzari,\u00a0and Josep Mallolas have nothing to disclose relating to this work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study was approved by the Ethics Committee of the Hospital Clinic of Barcelona (approval no. HCB\/2023\/0296).\u00a0Given the retrospective nature of the study, its potential utility for society, and in accordance with the relevant legislation (Articles 6.1.e and 9.2j of the General Data Protection Regulation [GDPR], as well as Additional Disposition 17.2.d of LOPD-GDD 3\/2018), the Ethics Committee of the Hospital Clinic of Barcelona waived the requirement for written informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}